Clinical trial
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's…
NCT05026866 · Eli Lilly and Company, Industry · Active, not recruiting
Key facts
| NCT number | NCT05026866 |
|---|---|
| Title | A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
| Official title | A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Donanemab, Placebo |
| Enrollment | 2,996 |
| Start date | Aug 27, 2021 |
| Primary completion | Nov 1, 2027 |
| Completion | Nov 1, 2027 |
| First posted | Aug 30, 2021 |
| Last update posted | Jan 21, 2026 |
| Countries | Japan, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- 100–999 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: